Patients who died exhibited significantly higher solCD44 and protein as compared with those who lived (solCD44:p = 0.016, protein:p = 0.001).37In a systematic review and meta-analysis including 15 studies conducted by Chen et al, it was found that the total percentage of CD44 expression was 57.8%, with 49.3% in oral cancer patients, 66.4% in the pharynx, and 54.7% in larynx cancer patients expressing CD44. This evidence concerns the gene CD44 and laryngeal neoplasm.